Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Blockade of the PD-1/PD-L1 immunologic checkpoint using monoclonal antibodies has provided breakthrough therapies against cancer in the recent years. Nevertheless, intrinsic disadvantages of therapeutic antibodies may limit their applications. Thus, blocking of the PD-1/PD-L1 interaction by small mo...

Full description

Bibliographic Details
Main Authors: Fengling Wang, Wenling Ye, Shuang Wang, Yongxing He, Haiyang Zhong, Yuwei Wang, Yongchang Zhu, Jianting Han, Zhitong Bing, Shaoping Ji, Huanxiang Liu, Xiaojun Yao
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
PD-1
PD-L1
Inhibitor
APBC
Cancer immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558621000026

Internet

http://www.sciencedirect.com/science/article/pii/S1476558621000026

Similar Items